ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback